SCHEMBL6533548

SCHEMBL6533548

C[N+]1(CCN=C=NC2CCCCC2)CCOCC1.Cc1ccc(S(=O)(=O)[O-])cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Known targets — ChEMBL curated mechanism

CHRM1CHRM2CHRM3CHRM4CHRM5SLC6A2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 1.00
CYP1A2 P05177 1/20 0.39
ALDH1A1 P00352 2/20 0.33
CYP3A4 P08684 1/20 0.32
TSHR P16473 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
TERT O14746 1/20 0.30
KDM4E B2RXH2 1/20 0.30
PKM P14618 1/20 0.30
ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3422484 0.94 CYP2C9 (0.89) CYP2C9CYP1A2ALDH1A1
SCHEMBL2534752 0.91 CYP2C9 (0.84) CYP2C9CYP1A2ALDH1A1CYP3A4TSHR
SCHEMBL729006 0.82 CYP2C9 (0.68) CYP2C9CYP1A2ALDH1A1
SCHEMBL18954292 0.73 CYP2C9 (0.56) CYP2C9ALDH1A1CYP3A4MEN1KMT2A
SCHEMBL3459786 0.73 CYP1A2 (0.65) CYP2C9CYP1A2ALDH1A1TSHRMEN1
SCHEMBL9332771 0.72 CYP2C9 (0.56) CYP2C9CYP1A2ALDH1A1CYP3A4TSHR
SCHEMBL6533549 0.72 CYP2C9 (0.56) CYP2C9ALDH1A1CYP3A4TSHRMEN1
SCHEMBL4757145 0.71 CYP2C9 (0.54) CYP2C9ALDH1A1CYP3A4MEN1KMT2A
P-Xylene SCHEMBL3752326 0.71 CYP1A2 (0.70) CYP2C9CYP1A2ALDH1A1TSHR
SCHEMBL9194077 0.71 CYP1A2 (0.61) CYP2C9CYP1A2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-12508321-B2 Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers HANGZHOU DAC BIOTECH CO., LTD. (CN) 2025-12-30 US claimed
US-12496351-B2 Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers HANGZHOU DAC BIOTECH CO., LTD. (CN) 2025-12-16 US claimed
CN-119838022-A Amatoxin conjugates containing branched linkers 杭州多禧生物科技有限公司 2025-04-18 CN claimed
CN-118557747-A Conjugates of cell binding molecules and camptothecin analogs 杭州多禧生物科技有限公司 2024-08-30 CN claimed
US-20230241241-A1 CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-08-03 US claimed
EP-4217364-A1 METHODS OF IDENTIFYING PROTEIN BINDING SITES ON RNA The Regents of the University of California (US) 2023-08-02 EP claimed
US-20230165930-A1 CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-06-01 US claimed
CN-116143678-A Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof 杭州多禧生物科技有限公司 2023-05-23 CN claimed
US-20230149502-A1 CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-05-18 US claimed
CN-115443134-A Conjugates of cell binding molecules and camptothecin analogs 杭州多禧生物科技有限公司 2022-12-06 CN claimed
CN-115300640-A Novel linkers and their use for specific coupling of drugs and biomolecules 杭州多禧生物科技有限公司 2022-11-08 CN claimed
US-20220313836-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2022-10-06 US claimed
US-20220313837-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2022-10-06 US claimed
US-20220313838-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2022-10-06 US claimed
EP-3991752-A1 CELL-BINDING MOLECULE-TUBULYSIN DERIVATIVE CONJUGATE AND PREPARATION METHOD THEREFOR Hangzhou Dac Biotech Co., Ltd (CN) 2022-05-04 EP claimed
EP-3986463-A1 A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS Hangzhou Dac Biotech Co., Ltd. (CN) 2022-04-27 EP claimed
WO-2022067036-A1 METHODS OF IDENTIFYING PROTEIN BINDING SITES ON RNA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-03-31 WO claimed
CN-114040778-A Cell binding molecule-Tubulysin derivative conjugate and preparation method thereof 杭州多禧生物科技有限公司 2022-02-11 CN claimed
CN-114040779-A Conjugates of cell binding molecules containing branched linkers and cytotoxic agents 杭州多禧生物科技有限公司 2022-02-11 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165930-A1 CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS TEKT1, CD2BP2, TEK CYP2C9 4809/4885CYP1A2 4877/4885ALDH1A1 4567/4885
US-12508321-B2 Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers CD4, CD2, B2M CYP2C9 4672/4885CYP1A2 4777/4885ALDH1A1 2817/4885
US-12496351-B2 Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers CD2BP2, DCLRE1A, EPCAM CYP2C9 4021/4885CYP1A2 4497/4885ALDH1A1 618/4885
US-20220313836-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS CD2BP2, DCLRE1A, EPCAM CYP2C9 4021/4885CYP1A2 4497/4885ALDH1A1 618/4885
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS DCLRE1A, CCR3, CCR8 CYP2C9 3299/4885CYP1A2 4265/4885ALDH1A1 2641/4885
US-20220313837-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS CD2BP2, DCLRE1A, EPCAM CYP2C9 4021/4885CYP1A2 4497/4885ALDH1A1 618/4885
US-20230149502-A1 CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS TEKT1, CD2BP2, TEK CYP2C9 4809/4885CYP1A2 4877/4885ALDH1A1 4567/4885
US-20220313838-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS CD2BP2, DCLRE1A, EPCAM CYP2C9 4021/4885CYP1A2 4497/4885ALDH1A1 618/4885
US-20230241241-A1 CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS CD4, DCLRE1A, TOP1 CYP2C9 4216/4885CYP1A2 4102/4885ALDH1A1 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.